DE69429351D1 - Verwendung von vitamin d und seinen derivaten zur herstellung eines medikamentes zum schutz vor neuronenverlust - Google Patents

Verwendung von vitamin d und seinen derivaten zur herstellung eines medikamentes zum schutz vor neuronenverlust

Info

Publication number
DE69429351D1
DE69429351D1 DE69429351T DE69429351T DE69429351D1 DE 69429351 D1 DE69429351 D1 DE 69429351D1 DE 69429351 T DE69429351 T DE 69429351T DE 69429351 T DE69429351 T DE 69429351T DE 69429351 D1 DE69429351 D1 DE 69429351D1
Authority
DE
Germany
Prior art keywords
vitamin
compound
neuron loss
against neuron
protect against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69429351T
Other languages
English (en)
Other versions
DE69429351T2 (de
Inventor
Philip W Landfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky
Original Assignee
University of Kentucky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kentucky filed Critical University of Kentucky
Application granted granted Critical
Publication of DE69429351D1 publication Critical patent/DE69429351D1/de
Publication of DE69429351T2 publication Critical patent/DE69429351T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Moving Of Heads (AREA)
DE69429351T 1993-07-15 1994-07-14 Verwendung von vitamin d und seinen derivaten zur herstellung eines medikamentes zum schutz vor neuronenverlust Expired - Fee Related DE69429351T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9197693A 1993-07-15 1993-07-15
PCT/US1994/007917 WO1995002409A2 (en) 1993-07-15 1994-07-14 Use of vitamin d and derivatives thereof for the manufacture of a medicament for protection against neuron loss

Publications (2)

Publication Number Publication Date
DE69429351D1 true DE69429351D1 (de) 2002-01-17
DE69429351T2 DE69429351T2 (de) 2002-05-23

Family

ID=22230588

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429351T Expired - Fee Related DE69429351T2 (de) 1993-07-15 1994-07-14 Verwendung von vitamin d und seinen derivaten zur herstellung eines medikamentes zum schutz vor neuronenverlust

Country Status (10)

Country Link
US (1) US5939407A (de)
EP (1) EP0710112B1 (de)
JP (1) JPH09507830A (de)
AT (1) ATE209921T1 (de)
AU (1) AU7333694A (de)
CA (1) CA2167171C (de)
DE (1) DE69429351T2 (de)
ES (1) ES2166377T3 (de)
IL (1) IL110309A0 (de)
WO (1) WO1995002409A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010012770A (ko) 1997-05-22 2001-02-26 세파론, 인코포레이티드 비타민 ｄ 유사체 및 그 뉴런 효과
WO1999059596A1 (en) * 1998-05-15 1999-11-25 The Board Of Trustees Of Leland Stanford Junior University Glucocorticoid receptor antagonists for the treatment of dementia
EP1280546A4 (de) * 2000-05-09 2005-02-23 Childrens Medical Center Methode und verbindung zur behandlung von angiogenese
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
WO2002036605A2 (en) * 2000-11-03 2002-05-10 Washington University Estrone-derivatives having cytoprotective activity
AU2002228891A1 (en) * 2000-11-17 2002-05-27 Washington University Cytoprotective estrogen derivatives
JP2005512949A (ja) * 2001-05-04 2005-05-12 コーセプト セラピューティクス， インコーポレイテッド グルココルチコイドレセプターに特異的なアンタゴニストを使用して、せん妄を処置する方法
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
WO2005116047A2 (en) * 2004-05-27 2005-12-08 Migenix Corp. 2-substituted 17-imino estrogen compounds for cytoprotection
WO2006125324A1 (en) * 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
JP2007023010A (ja) * 2005-07-19 2007-02-01 Toshiro Azegami 閉経後のホルモンバランス調整及びパーキンソン症の予防改善目的の経口組成物
ES2645816T3 (es) * 2006-04-03 2017-12-07 Accera, Inc. Uso de compuestos cetogénicos para el tratamiento de la alteración de la memoria asociada a la edad
US20100204192A1 (en) * 2007-06-11 2010-08-12 University Of Sourthern California Agents, compositions and methods for enhancing neurological function
US8969329B2 (en) * 2007-06-11 2015-03-03 University Of Southern California Allopregnanolone in a method for enhancing neurological function
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
EP2363119A1 (de) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Neue pharmazeutische Zusammensetzung, die zur Behandlung von Patienten mit neurodegenerativen oder neurovaskulären Erkrankungen geeignet ist
FR2965178B1 (fr) * 2010-09-29 2012-10-05 Sebastien Lasnier Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer
DK2753632T3 (da) 2011-09-08 2023-07-10 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelse heraf
ES2886506T3 (es) 2013-03-13 2021-12-20 Sage Therapeutics Inc Esteroides neuroactivos
EP2988618A1 (de) 2013-03-27 2016-03-02 DSM IP Assets B.V. Verwendung von 25-hydroxyvitamin-d3 zur verbesserung von ausführungsfunktionen
US20140296190A1 (en) * 2013-03-27 2014-10-02 Dsm Ip Assets B.V. Marketing the use of 25-hydroxyvitamin d3 to enhance cognition
ES2536256B2 (es) * 2013-11-20 2016-02-01 Universidade De Santiago De Compostela Análogos de vitamina d con interés farmacéutico
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE055199T2 (hu) 2015-07-06 2021-11-29 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
AU2016289967B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
SI3436022T1 (sl) 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA45598B1 (fr) 2016-07-07 2021-09-30 Sage Therapeutics Inc Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
CA3038900A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
TWI815800B (zh) 2016-10-18 2023-09-21 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
EP3529256B1 (de) 2016-10-18 2023-08-09 Sage Therapeutics, Inc. Oxysterole und verfahren zur verwendung davon
WO2021217086A1 (en) 2020-04-24 2021-10-28 The Johns Hopkins University Compositions and methods comprising dendrimers and therapeutic agents
WO2023028554A1 (en) 2021-08-25 2023-03-02 Neuraly, Inc. Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63104926A (ja) * 1986-10-21 1988-05-10 Teijin Ltd 老年性痴呆症治療又は予防剤
FR2639225B1 (fr) * 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
US4957909A (en) * 1989-05-04 1990-09-18 American Home Products Corporation Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents
US5089517A (en) * 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5196421A (en) * 1991-06-05 1993-03-23 Eli Lilly And Company Excitatory amino acid receptor antagonists in methods for the use thereof
US5153196A (en) * 1991-06-05 1992-10-06 Eli Lilly And Company Excitatory amino acid receptor antagonists and methods for the use thereof

Also Published As

Publication number Publication date
ATE209921T1 (de) 2001-12-15
EP0710112B1 (de) 2001-12-05
IL110309A0 (en) 1994-10-21
JPH09507830A (ja) 1997-08-12
EP0710112A1 (de) 1996-05-08
DE69429351T2 (de) 2002-05-23
CA2167171A1 (en) 1995-01-26
CA2167171C (en) 2007-04-24
WO1995002409A2 (en) 1995-01-26
US5939407A (en) 1999-08-17
WO1995002409A3 (en) 1995-04-27
ES2166377T3 (es) 2002-04-16
AU7333694A (en) 1995-02-13

Similar Documents

Publication Publication Date Title
DE69429351D1 (de) Verwendung von vitamin d und seinen derivaten zur herstellung eines medikamentes zum schutz vor neuronenverlust
BR0309623A (pt) Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
MD895B2 (ro) Preparat sinergetic şi procedeu de distrugere selectivă a buruienilor
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
DE69310634D1 (de) Verwendung von Taxol zur Herstellung eines Arzneimittels zur Behandlung von Krebs
CA2202879A1 (en) Calcium receptor-active compounds
DE3687501D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.
ATE286384T1 (de) Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan
ATE467616T1 (de) Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
NO20005161L (no) N,N-disubstituerte amider som inhiberer bindingen av integriner til deres reseptorer
ID26956A (id) Pencegahan raf kinase menggunakan simetris dan nonsimetris yang digantikan diphenil urea
ATE104855T1 (de) Verwendung von inositoltrisphosphat zur herstellung eines arzneimittels gegen knochenerkrakungen.
DE58906387D1 (de) Verwendung von Benzimidazolen zur Herstellung eines Arzneimittels mit antiischämischen Wirkungen am Herzen und dessen Kombinationen mit Beta-Blockern oder Bradycardica.
DE59209728D1 (de) VERWENDUNG VON ANTAGONISTEN ODER PARTIELLEN AGONISTEN AM 5-HT 1a-REZEPTOR ZUR BEHANDLUNG UND PRÄVENTION VON KOGNITIVEN STÖRUNGEN
BRPI0410654A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
DE69330150D1 (de) Pharmazeutische Zusammensetzungen zur transdermalen Verabreichung von Melatonin und/oder seine Analoge
NO994395L (no) Stabilt, fast preparat som inneholder vitamin D3 og trikalsiumfosfat
ATE141160T1 (de) Ein flurbiprofen enthaltendes akutarzneimittel und seine verwendung
ATE160143T1 (de) 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten
BR9811829A (pt) Processos para fumegação do solo contendo organismos deletérios controlando ao mesmo tempo a fitotoxicidade, e, para controlar organismos deletérios no solo
ATE147267T1 (de) Verwendung von 24,25-dihydroxyvitamin-d3 zur herstellung eines arzneimittel zur behandlung der rachitis
DE69628430D1 (de) Verwendung von lactoferrin zur prävention des nachoperativen astigmatismus
NO304518B1 (no) Benzimidazoler, anvendelse derav for fremstilling av et medikament, samt farmas°ytiske preparater som omfatter dem
Dalessio Medical treatment of tic douloureux
ATE186214T1 (de) Verwendung von rosmanolderivaten zur herstellung von antiradikalischen und/oder antilipoperoxidativen und/oder hepatotropen arzneistoffen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee